IRC
MYGN icon

Investors Research Corp’s Myriad Genetics MYGN Stock Holding History

Investors Research Corp’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,400
Closed -$39K – 1126
2019
Q2 		$39K Hold
1,400
– – 0.02% 539
2019
Q1 		$46K Buy
+1,400
New +$42.6K 0.02% 521

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Investors Research Corp's MYGN Position: Q3 2019 in Review

Investors Research Corp sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 1,400 shares — an estimated $39K sold.

Investors Research Corp first reported a position in MYGN in Q1 2019 and held it in 2 quarters. The position peaked at $46K in Q1 2019. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

  • Investors Research Corp reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
  • Investors Research Corp sold 1,400 Myriad Genetics shares in Q3 2019, an estimated $39K.
  • Investors Research Corp first reported a position in Myriad Genetics in Q1 2019 and held it in 2 quarters.
  • Investors Research Corp's Myriad Genetics position peaked at $46K in Q1 2019.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Investors Research Corp's 13F filing for Q3 2019, filed 22 Oct 2019.